ContextVision just launched the company’s first CE marked digital pathology product based on artificial intelligence. In this podcast the company’s CEO Fredrik Palm and Dr. Filippo Fraggetta, the chief pathologist at the Cannizzaro Hospital, will talk about the revolution we are approaching within digital pathology. Listen here
ContextVision today announced that its first digital pathology product in a planned portfolio has been granted CE mark status. This means that INIFY® Prostate Screening is now available for routine clinical use within the European Union.
ContextVision announces first digital pathology patent granted for its unique and objective data-generation method
Master Annotation method has received patent protection in the U.S. The U.S. Patent and Trademark Office (USPTO) has granted a patent to ContextVision for this invention, titled “method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide”.
ContextVision’s Deep Learning experts will hold an oral presentation at the Medical Imaging & Deep Learning conference in London July 8–10
This paper presents an interesting and novel idea of a deep learning (DL) framework to segment potentially cancerous areas in prostate biopsies using semi-automatically generated data. The application of this paper is quite innovative and the proposed method seems to be a direct assistance to the clinical routine.
ContextVision Earns Acclaim from Frost & Sullivan for Its AI-powered INIFY™ Prostate Cancer Screening Platform
Based on its recent analysis of the European prostate cancer screening market, Frost & Sullivan recognises the Stockholm-based ContextVision AB with the 2019 European Technology Leadership Award for its INIFY™ Prostate platform.
ContextVision will have exclusive rights to the scanning cohort and access to anonymized associated clinical data - with cleared and structured histopathological descriptions, diagnosis and outcome data - for the defined patient cohorts and all commercial rights from output based on the data.The agreement gives ContextVision an opportunity to create AI-based decision support tools that will help doctors make more accurate treatment decisions. Today, many cancer patients suffer from life impairing side effects from treatments they did not need while other patients do not get treatment which is necessary.